Steris PLC (STE) has seen a positive surge in performance, despite underperforming in the market on certain days. Assenagon Asset Management S.A
sold 8,912 shares while Nisa Investment Advisors LLC
bought 84 shares. Steris reported Q2, Q3, and Q4 of 2024, and Q1 of 2025's numbers that solidified its buy thesis, witnessing strong earnings and revenue growth. Despite Q1 earnings beating estimates, its
operating margin fell. However, some insider sales have been reported. Raymond James & Associates and other financial services continued their investment, implying confidence in Steris. Steris'
expanding AST business and
new offerings are positively influencing growth, highlighting it as a top growth stock for the long-term. Its first quarter of FY2025 had revenue hitting $1.3 billion and GAAP EPS at $1.41, both surpassing estimates. Uncertainty surrounding its fundamentals does exist. Steris' decision to sell the dental unit to HuFriedy, aimed at debt reduction, sold off dental segment to HuFriedy Group with certain conditions, and layoffs as part of restructuring indicate its effort for more concise focus. Steris does plan to close plants in Brazil and England, costing 'less than 200' jobs. Despite a downgrade to 'Hold' by StockNews.com, Steris had days where it outperformed the market. Furthermore, Steris announced its CEO succession plan, two key acquisitions, and a deal to sell its renal care business
Steris Plc STE News Analytics from Tue, 11 Sep 2007 07:00:00 GMT to Sun, 25 Aug 2024 15:11:31 GMT -
Rating 6
- Innovation 3
- Information 7
- Rumor -3
